NCT05538897

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

Public trial-level signal summary for this oncology Phase 2 record.

Record overview

Status and phase

Status: ACTIVE_NOT_RECRUITING

Phase: PHASE1, PHASE2

Sponsor: National Cancer Institute (NCI)

Condition: FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Metastatic Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma

Signal summary

Public flags

Status signal: Low Signal

Timeline signals: long_recruitment_duration_signal

Results signal: Low Signal

Operational burden: strict_eligibility_signal

Stopped reason

Context when available

No stop reason available in the current public record.